Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com

imipridones

Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma

Clin Cancer Res. 2018 PMID: 30037819

View Publication